There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aridis Pharmaceuticals (ARDS – Research Report) and Minerva Neurosciences (NERV – Research Report) with bullish sentiments.
Aridis Pharmaceuticals (ARDS)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aridis Pharmaceuticals, with a price target of $19.00. The company’s shares closed last Monday at $1.48.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aridis Pharmaceuticals with a $19.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Minerva Neurosciences (NERV)
JMP Securities analyst Jason Butler reiterated a Buy rating on Minerva Neurosciences today and set a price target of $21.00. The company’s shares closed last Monday at $4.50, close to its 52-week low of $2.51.
According to TipRanks.com, Butler has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Minerva Neurosciences has an analyst consensus of Moderate Buy, with a price target consensus of $13.50, which is a 310.3% upside from current levels. In a report issued on August 10, BTIG also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARDS:
